Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Neurogene, Inc. Common Stock

NGNE

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Last trade $22.91
Day change -$0.39 (-1.67%)
Day range $21.41 – $23.71
Volume 214,759
Market cap $482M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$482.33M
Price / earnings
—
Price / book
1.36×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.18×

Profitability

Earnings per share
-$5.76
Return on assets
-31.54%
Return on equity
-33.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
19.97×
Quick ratio
19.97×
Cash ratio
4.35×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$97.53M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NGNE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$8.85M$11.2M$8.2M$6.89M$6.56M$6.72M$8.16M$6.17M
Research and development$23.52M$25.47M$25.15M$20.64M$17.24M$19.37M$17.76M$15.35M
Total operating expenses$32.38M$36.67M$33.35M$27.53M$23.8M$26.08M$25.92M$21.51M
Operating income-$32.38M-$36.67M-$33.35M-$27.53M-$23.8M-$26.08M-$25.92M-$21.51M
Interest expense-$29K$0$0-$1K-$43K-$1K-$2K-$2K
Income before taxes-$29.02M-$34.49M-$30.93M-$24.74M-$20.95M-$22.02M-$22.65M-$19.51M
Income taxes$0$0$0$0$0$0$0$0
Net income-$29.02M-$34.49M-$30.93M-$24.74M-$20.95M-$22.02M-$22.65M-$19.51M
Net income attributable to common shareholders-$29.02M-$34.49M-$30.93M-$24.74M-$20.95M-$22.02M-$22.65M-$19.51M
EBITDA-$31.56M-$35.86M-$32.5M-$26.75M-$23.03M-$25.33M-$25.17M-$20.73M
Basic earnings per share-$1.05-$1.53-$1.39-$1.12-$0.99-$1.05-$1.08-$1.00
Diluted earnings per share-$1.05-$1.53-$1.39-$1.12-$0.99-$1.05-$1.08-$1.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?

Neurogene (NGNE) closed at $25.28 with a mean analyst price target of $76.67, suggesting 203.3% upside potential. The stock has gained 17.3% over the past four weeks. While price targets should be treated with skepticism, the company shows positive earnings estimate revisions and holds a Zacks Rank #2 (Buy) rating, indicating potential near-term upside.

Zacks Investment Research

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 25, 20231-for-5reverse split